Alkermes Investigational Site

Cincinnati, Ohio 45245

5 studies enrolling now · 12 studies all time

What they study most

Bipolar I Disorder, Idiopathic Hypersomnia, Major Depressive Disorder, Narcolepsy Type 1, Narcolepsy Type 2, Refractory Major Depressive Disorder, Schizophrenia, Schizophreniform Disorder, Schizophreniform Disorders

Studies at this site

• A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 — Recruiting now
• A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 — Recruiting now
• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia — Recruiting now
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) — Completed
• Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects — Enrolling by invitation
• Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 — Completed
• Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder — Completed
• A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) — Stopped early
• A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) — Completed
• A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study — Completed
• A Long-Term Safety Study of ALKS 5461 — Completed